Efaproxiral (Allos Therapeutics).
Allos Therapeutics Inc is developing the hemoglobin allosteric modifier efaproxiral as a potential radiosensitizer and chemotherapy enhancer in cancer therapy.
Kolman
Ada
A
Department of Molecular Biology and Functional Genomics, Stockholm University, SE-106 91 Stockholm, Sweden. ada.kolman@molbio.su.se
D000814:Aniline Compounds / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011422:Propionates / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000814:Aniline Compounds; D011422:Propionates; D011838:Radiation-Sensitizing Agents; C067396:efaproxiral